BioTuesdays

Category - Markets

Autolus Logo
Markets

HCW cuts Autolus PT to $24 from $41

H.C. Wainwright lowered its price target for Autolus Therapeutics plc (NASDAQ:AUTL) to $24 from $41 after significant changes to its pipeline and timelines were disclosed in the company’s second quarter results. The...

August 12, 2019
Precision Biosciences
Markets

BTIG starts Precision BioSciences at buy; PT $22

BTIG initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $22 price target, representing upside of approximately 100% from a closing price of $10.98 on Aug. 8. “While Precision only recently...

August 9, 2019
ViewRay Logo
Markets

BTIG cuts ViewRay PT to $6 from $10

BTIG lowered its price target for ViewRay (NASDAQ:VRAY) to $6 from $10 after the company reported second quarter results. The stock closed at $6.74 on Aug. 8 but was down to $3.35 in after hours trading. ViewRay, which...

August 9, 2019
Markets

WB starts Addus HomeCare at OP

William Blair initiated coverage of Addus HomeCare (NASDAQ:ADUS) with an “outperform” rating, saying the company is one of the few ways for public market investors to play the in-home healthcare delivery theme, with a...

August 9, 2019
Markets

BTIG starts Cellectis at buy; PT $37

BTIG launched coverage of Cellectis SA (NASDAQ:CLLS; Euronext Growth:ALCLS) with a “buy” rating and $37 price target. The stock closed at $13.86 on Aug. 8. “Despite the initial positive reaction from investors to...

August 9, 2019
Organovo Holdings
Markets

HCW cuts Organovo to neutral and removes PT

H.C. Wainwright downgraded Organovo Holdings (NASDAQ:ONVO) to “neutral” from “buy” and removed its price target after the company engaged a financial advisor to assist management in exploring strategic alternatives. The...

August 8, 2019
Inogen
Markets

Stifel cuts Inogen to hold; PT to $48 from $85

Stifel downgraded Inogen (NASDAQ:INGN) to “hold” from “buy” and lowered its price target to $48 from $85 after the company’s second quarter sales missed consensus estimates and it reduced 2019 guidance. The stock closed...

August 8, 2019
TransEnterix Logo
Markets

BTIG halves TransEnterix PT to $1.50 from $3

BTIG halved its price target for TransEnterix (NASDAQ:TRXC) to $1.50 from $3 after the company’s second quarter results fell short of guidance and consensus estimates. The stock closed at $1.15 on Aug. 7. TransEnterix...

August 8, 2019
Markets

HCW cuts Rexahn Pharma to neutral; PT to $3 from $23

H.C. Wainwright downgraded Rexahn Pharmaceuticals (NASDAQ:REXN) to “neutral” from “buy” and slashed its price target to $3 from $23 after a disappointing update from the company’s Phase 2a pancreatic cancer study...

August 8, 2019
Markets

WB starts Actinium Pharma at OP

William Blair launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with an “outperform” rating based on its view that the company’s potent and specific radiopharmaceuticals for improving treatment options of...

August 8, 2019